SG11201603081WA - Methods of treating and preventing radiation damage - Google Patents

Methods of treating and preventing radiation damage

Info

Publication number
SG11201603081WA
SG11201603081WA SG11201603081WA SG11201603081WA SG11201603081WA SG 11201603081W A SG11201603081W A SG 11201603081WA SG 11201603081W A SG11201603081W A SG 11201603081WA SG 11201603081W A SG11201603081W A SG 11201603081WA SG 11201603081W A SG11201603081W A SG 11201603081WA
Authority
SG
Singapore
Prior art keywords
treating
methods
radiation damage
preventing radiation
preventing
Prior art date
Application number
SG11201603081WA
Inventor
Stephen Marcus
Original Assignee
Cantex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantex Pharmaceuticals Inc filed Critical Cantex Pharmaceuticals Inc
Publication of SG11201603081WA publication Critical patent/SG11201603081WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201603081WA 2013-10-22 2014-10-21 Methods of treating and preventing radiation damage SG11201603081WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361894343P 2013-10-22 2013-10-22
PCT/US2014/061634 WO2015061358A1 (en) 2013-10-22 2014-10-21 Methods of treating and preventing radiation damage

Publications (1)

Publication Number Publication Date
SG11201603081WA true SG11201603081WA (en) 2016-05-30

Family

ID=52993467

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201603081WA SG11201603081WA (en) 2013-10-22 2014-10-21 Methods of treating and preventing radiation damage

Country Status (11)

Country Link
US (1) US20160287626A1 (en)
EP (1) EP3060243A4 (en)
JP (1) JP2016534057A (en)
KR (1) KR20160101898A (en)
CN (1) CN105848672A (en)
AU (1) AU2014340238A1 (en)
CA (1) CA2928585A1 (en)
HK (1) HK1223021A1 (en)
IL (1) IL245344A0 (en)
SG (1) SG11201603081WA (en)
WO (1) WO2015061358A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201914117QA (en) 2012-05-09 2020-02-27 Cantex Pharmaceuticals Inc Treatment Of Myelosuppression
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
KR20190063536A (en) * 2017-11-30 2019-06-10 주식회사 엔지켐생명과학 Composition for preventing or treating acute radiation syndrome comprising 1-palmitoyl-2-linoleoyl-3-acetylglycerol
CN113164430A (en) * 2018-06-03 2021-07-23 格莱科米拉治疗公司 Methods for preventing severe health consequences and/or tissue damage following exposure to ionizing radiation and/or chemotherapy
KR102090489B1 (en) 2018-10-19 2020-03-18 한국과학기술연구원 Ammonia gas detecting sensor using graphene doped with copper oxide nanopaticles and ammonia gas detecting device comprising the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2290563A1 (en) * 1997-05-30 1998-12-03 Arch Development Corporation P-selectin translocation to vascular epithelial lumen by ionizing radiation
CN1270034A (en) * 1999-11-04 2000-10-18 第一军医大学珠江医院 application of coenzyme in histocyte chemistry and prevention and cure of radiation injury
ZA200801696B (en) * 2005-07-22 2009-08-26 Univ California Heparin compositions and selection inhibition
JP2010534672A (en) * 2007-07-23 2010-11-11 ユニバーシティ オブ ユタ リサーチ ファウンデーション Method for blocking glycation end product receptor (RAGE) ligation
CN102177180A (en) * 2008-04-04 2011-09-07 犹他州大学研究基金会 Alkylated sem-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US8906883B2 (en) * 2009-06-10 2014-12-09 Exthera Ab Treatment of oral mucositis by administering an ionic complex of chitosan and a negatively charged polysaccharide selected from heparin, heparan sulfate and dextran sulfate
US20120196828A1 (en) * 2011-02-01 2012-08-02 Paringenix, Inc. Sensitization of cancer cells to treatment
SG10201914117QA (en) * 2012-05-09 2020-02-27 Cantex Pharmaceuticals Inc Treatment Of Myelosuppression

Also Published As

Publication number Publication date
JP2016534057A (en) 2016-11-04
IL245344A0 (en) 2016-06-30
HK1223021A1 (en) 2017-07-21
CN105848672A (en) 2016-08-10
EP3060243A4 (en) 2017-03-29
WO2015061358A1 (en) 2015-04-30
CA2928585A1 (en) 2015-04-30
EP3060243A1 (en) 2016-08-31
KR20160101898A (en) 2016-08-26
US20160287626A1 (en) 2016-10-06
AU2014340238A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
HK1216991A1 (en) Cancer vaccines and methods of treatment using the same
HK1218506A1 (en) Methods of treating melanoma
HK1217908A1 (en) Methods of treating cholangiocarcinoma
GB2518286B (en) Security device and method of manufacture
GB2517079B (en) Security devices and methods of manufacture
GB201301790D0 (en) Security devices and methods of manufacture thereof
GB201401761D0 (en) Security devices and methods of manufacture thereof
GB201320723D0 (en) Composition and methods of treatment
GB2510381B (en) Security devices and methods of manufacture thereof
EP2999474A4 (en) Therapeutic and method of use
SG11201509703YA (en) Energy harvesting device and method of harvesting energy
HK1213817A1 (en) Methods of treating cancer
HK1223021A1 (en) Methods of treating and preventing radiation damage
SG10201710538XA (en) Compositions and methods for treating skin
HK1223844A1 (en) Method for the management of cancer and treatment of cancer comorbidities
HK1219513A1 (en) Methods of treating cancer
HK1222389A1 (en) Treatment of pulmonary and other conditions
HK1220396A1 (en) Treatment and prevention of acne
GB201410954D0 (en) Skin treatment devices and methods
TWI561255B (en) Use of umirolimus and its derivatives for treating cancer
SG10201707533TA (en) Phototherapy devices and methods
GB201317373D0 (en) Treatment and prevention of cancer
GB201321848D0 (en) Lock means and method of use thereof
GB201303115D0 (en) Detection and treatment of liver cancer